Drug Insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting

@article{Oo2005DrugIN,
  title={Drug Insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting},
  author={T. Oo and P. Hesketh},
  journal={Nature Clinical Practice Oncology},
  year={2005},
  volume={2},
  pages={196-201}
}
  • T. Oo, P. Hesketh
  • Published 2005
  • Medicine
  • Nature Clinical Practice Oncology
    • Nausea and vomiting remain among the most feared side effects of chemotherapy for cancer patients. Significant progress has been made in the last 15 years in developing more effective and better-tolerated measures to minimize chemotherapy-induced nausea and vomiting (CINV). During the 1990s, the selective 5-hydroxytryptamine receptor antagonists were first introduced for the treatment of CINV, and resulted in more effective and better tolerated treatment of CINV. Despite recent progress… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    36 Citations
    Highly Influencial Citations
    3
    Background Citations
    16

    Tables and Topics from this paper.

    Tables

    Explore Further: Topics Discussed in This Paper

    36 Citations
    Citation Type

    Citation Type

    Palonosetron Hydrochloride in the Treatment of Chemotherapy-Induced Nausea and Vomiting
    • 2
    Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis.
    • 21
    of chemotherapy-Induced nausea and Vomiting
    Effect of Hydroxyzine in Controlling Acute Chemotherapy-Induced Vomiting in Children: A Randomised Trial
    • 3
    • PDF
    Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
    • 177
    The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: a retrospective study
    • 10
    Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
    • 137
    NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience.
    • M. Valerio, V. Gebbia, +5 authors Daniele Galanti
    • Medicine
    • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
    • 2020
    A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients.
    • 13
    • PDF
    Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial.

    References

    SHOWING 1-10 OF 19 REFERENCES
    Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists
    • P. Hesketh
    • Medicine
    • Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
    • 1994
    • 52
    Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting
    • 42
    Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
    • 424
    Clinical Science Review: Comparative Review of 5-HT3 Receptor Antagonists in the Treatment of Acute Chemotherapy-Induced Nausea and Vomiting
    • 136
    Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.
    • 141
    Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: A randomized double-blind trial in 866 patients.
    • 15
    Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy
    • 97
    • PDF
    The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials
    • 135
    The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    • 83
    The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
    • P. Hesketh, S. Grunberg, +11 authors K. Horgan
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2003
    • 693